64490-92-2
基本信息
托尔米汀钠
托美丁钠(二水)
2-[1-甲基-5-(4-甲基苯甲酰)吡咯-2-基]乙酸钠(二水)
1-METHYL-5-[P-TOLUOYL]PYRROLE-2-ACETIC ACID SODIUM SALT: DIHYDRATE
TOLMETIN SODIUM
TOLMETIN SODIUM SALT DIHYDRATE
TOLMETIN SODIUM SALT: DIHYDRATE
1h-pyrrole-2-aceticacid,1-methyl-5-(4-methylbenzoyl)-,sodiumsalt,dihydrate
sodium1-methyl-5-p-toluoylpyrrole-2-acetatedihydrate
sodiumtolmetindihydrate
tolmetinsodiumdihydrate
Tolmetinsodiumsaltdihydratecrystalline
1-methyl-5-(p-toluoyl)pyrrole-2-acetic acid sodium-potassium salt dihydrate
TOLMELINSODIUM
1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic Acid Sodium Dihydrate
1-Methyl-5-p-toluoylpyrrole-2-acetic Acid Sodium Dihydrate
5-[(p-Tolyl)carbonyl]-1-methylpyrrole-2-acetic Acid Sodium Dihydrate
McN 2559-21-98
Tolmene
1-Methyl-5-(p-toluoyl)pyrrole-2-acetic acid dihydrate sodium-potassium salt
Tolmetin dihydrate sodium salt
物理化学性质
| 熔点 | 155-157 (dec.) |
| 储存条件 | -20°C冷冻 |
| 溶解度 | 少许溶于甲醇和水 |
| 形态 | 固体 |
| 颜色 | 白色至米色 |
| 水溶解性 | 溶于水 |
| InChIKey | QQILXENAYPUNEA-UHFFFAOYSA-M |
| CAS 数据库 | 64490-92-2(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |   GHS07,GHS08 |
| 警示词 | 警告 |
| 危险性描述 | H302-H361d |
| 防范说明 | P202-P264-P270-P280-P301+P312-P308+P313 |
| 危险品标志 | Xn |
| 危险类别码 | R22-R38 |
| 安全说明 | S36 |
| WGK Germany | 3 |
| RTECS号 | UX9280000 |
| 海关编码 | 2933995500 |
知名试剂公司产品信息
托美丁钠(二水)价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | HY-B1489 | 托美丁钠(二水) Tolmetin sodium dihydrate | 64490-92-2 | 100mg | 500元 |
| 2024/11/08 | HY-B1489 | 托美丁钠(二水) Tolmetin sodium dihydrate | 64490-92-2 | 10mM * 1mLin DMSO | 550元 |
| 2024/11/08 | S4360 | 托美丁钠(二水) Tolmetin Sodium | 64490-92-2 | 25mg | 795.3元 |
常见问题列表
|
Human COX-1 0.35 μM (IC 50 ) |
Human COX-2 0.82 μM (IC 50 ) |
Tolmetin sodium dihydrate (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat.
Tolmetin sodium dihydrate (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner.
Tolmetin sodium dihydrate (0-100 μM) shows no effect on osteoblast growth.
Tolmetin sodium dihydrate (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg.
Tolmetin sodium dihydrate (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity.